Plasma histaminase activity in carcinoma of the cervix—Its clinical significance
✍ Scribed by Ashwi Birdi; Saroj Gupta; S. S. Gambhir
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 324 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Plasma histaminase activity has been estimated in 79 patients with squamous cell carcinoma of the cervix. The mean plasma histaminase value is significantly higher in patients than in controls (P < 0.001). The plasma histaminase activity falls significantly following radiotherapy (P < 0.001).
Pretreatment plasma histaminase values do not show any correlation with clinical stages and the posttreatment values decline significantly but remain higher in clinical stages I11 and IV than in stages I and 11. The increased plasma histaminase activity also reflects the degree of differentiation within the tumor. Further it is noted that the plasma histaminase value is inversely proportional to the radiation response. It is suggested that estimation of plasma histaminase activity can serve as an important marker in assessing the treatment response and monitoring the course of treatment.
📜 SIMILAR VOLUMES
The skillful help of Mrs. M. C. de Boer-Bisschops, Mrs. C. Kosterman-Claassen, Mr. R. Lodewijks, and Mrs. U. M. R. Vrij in performing the CEA assay, and of Mrs. A. Graafmans and Mrs. A. J. M. Pieterson-Scholts in collecting and handling the bloodsamples, is gratefully acknowledged.
## Abstract ## BACKGROUND The activation of the clotting‐fibrinolytic system in cancer patients is common and represents an unfavorable clinical sign. D‐dimer (DD) is a sensitive marker of fibrinolysis. ## METHODS The current study comprised 826 new lung carcinoma patients seen consecutively in
## BACKGROUND. Alterations in the expression of p53 tumor suppressor protein is a frequent event in human cancer but the practical implications of this phenomenon are yet to be fully exploited. The objective of this study was to determine the value of p53 accumulation as a marker of tumor progress